...specific cell population,” Redpin co-founder, President and CEO Elma Hawkins told BioCentury. Founded in 2017, Redpin Therapeutics Inc.... ...five-fold lower than that required for the drug to act as nicotine substitute. COMPANY PROFILE Redpin Therapeutics Inc....
...is developing therapies for cytopenias and myelodysplastic syndromes; oncolytic virus company Oncorus Inc.; chemogenetics company Redpin Therapeutics Inc....
...specific cell population,” Redpin co-founder, President and CEO Elma Hawkins told BioCentury. Founded in 2017, Redpin Therapeutics Inc.... ...five-fold lower than that required for the drug to act as nicotine substitute. COMPANY PROFILE Redpin Therapeutics Inc....
...is developing therapies for cytopenias and myelodysplastic syndromes; oncolytic virus company Oncorus Inc.; chemogenetics company Redpin Therapeutics Inc....